EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment Persistence and Variations in Prescribing Oral, Injectable, and Inhaled Corticosteroids: A Population‐Based Drug Utilisation Study

Eleni Domzaridou iD, Matthew J Carr iD, David M Williams iD, Anthony J Avery iD, Tjeerd van Staa iD, D Aled Rees iD, Darren M Ashcroft iD

Pharmacoepidemiology and Drug Safety · 2025

DOI: 10.1002/pds.70153 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Eleni Domzaridou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Nuffield Department of Population Health, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: Adrenal Cortex Hormones, Practice Patterns, Physicians'. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Royal College of Physicians, Addison's Disease Self-Help Group, National Institute for Health and Care Research (NIHR) Greater Manchester Patient Safety Research Collaboration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To examine variation in oral, injectable, and inhaled corticosteroid (CS) prescribing in primary care, exploring treatment persistence and coverage.

Methods

We examined patient‐level electronic health records from English general practices in the Clinical Practice Research Datalink Aurum database. We delineated a cohort of new users of oral, injectable, or inhaled CS with prescriptions issued between January 1, 2000, and June 30, 2021. Lorenz curves assessed potential prescribing skewness, and Kaplan–Meier (KM) plots estimated treatment persistence. The Proportion of Patients Covered (PPC) method estimated the proportion of patients still covered by treatment 1 year after initiation.

Results

We observed 1 942 571 CS users across 1471 general practices, with 20% of oral and inhaled CS users accounting for almost 80% of total CS use. Older patients with comorbidities including respiratory diseases (13.5%), skin conditions (5.8%), or inflammatory bowel diseases (1.6%) were more likely to be prescribed higher doses. The KM plots showed that 20% of oral and 50% of inhaled CS users were persistent after one and 2 months, respectively. The PPC method indicated that 30% of oral and 60% of inhaled CS users were covered by treatment 6 months post‐initiation. Some variation was observed when different grace periods were applied. Combined use of oral and inhaled CS was observed for 6.9% of patients.

Conclusion

A fifth of patients receiving CS accounted for over 80% of oral and inhaled CS prescribing in primary care. Identifying these patients is crucial for targeting future interventions to promote patient safety and cost‐effective CS use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenal Cortex HormonesPractice Patterns, Physicians'HumansAdministration, InhalationMaleFemaleAdministration, OralMiddle AgedAgedAdultPrimary Health CareYoung AdultInjectionsElectronic Health RecordsAdolescentDatabases, FactualChildAged, 80 and over

Stichwörter der Autor:innen

corticosteroidstreatment coveragetreatment persistence

Substanzen

Adrenal Cortex Hormones

Autor:innen und Institutionen

  • Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • National Institute for Health and Care Research (NIHR) Greater Manchester Patient Safety Research Collaboration (GM PSRC), School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Ma…
  • Centre for Pharmacoepidemiology and Drug Safety, Division of Pharmacy & Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
  • Neuroscience and Mental Health Innovation Institute, Cardiff University, Cardiff, UK.
  • Centre for Primary Care, School of Medicine, University of Nottingham, Nottingham, UK.
  • Centre for Health Informatics, Imaging and Data Science, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.

ORCID-Profile: Eleni Domzaridou, Matthew J Carr, David M Williams, Anthony J Avery, Tjeerd van Staa, D Aled Rees, Darren M Ashcroft

Förderung

  • Royal College of Physicians
  • Addison's Disease Self-Help Group
  • National Institute for Health and Care Research (NIHR) Greater Manchester Patient Safety Research Collaboration
  • National Institute for Health and Care Research

Zitieren

APA

Domzaridou, E., Carr, M. J., Williams, D. M., Avery, A. J., van Staa, T., Rees, D. A., & Ashcroft, D. M. (2025). Treatment Persistence and Variations in Prescribing Oral, Injectable, and Inhaled Corticosteroids: A Population‐Based Drug Utilisation Study. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70153

Vancouver

Domzaridou E, Carr MJ, Williams DM, Avery AJ, van Staa T, Rees DA, et al. Treatment Persistence and Variations in Prescribing Oral, Injectable, and Inhaled Corticosteroids: A Population‐Based Drug Utilisation Study. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70153

BibTeX
@article{Domzaridou2025,
  author = {Domzaridou, Eleni and Carr, Matthew J and Williams, David M and Avery, Anthony J and van Staa, Tjeerd and Rees, D Aled and Ashcroft, Darren M},
  title = {Treatment Persistence and Variations in Prescribing Oral, Injectable, and Inhaled Corticosteroids: A Population‐Based Drug Utilisation Study},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2025},
  doi = {10.1002/pds.70153}
}
Kostenlos starten →